Why does the body suppress its own immune response after trauma and surgery — and why might that be a problem in cancer surgery specifically?

Any trauma or surgical intervention triggers the release of anti-inflammatory mediators and cytokines that dampen immune function. At first glance this seems counterproductive — a weaker immune system is a clear liability, particularly with respect to infection. So why has evolution favored this response?

1. Inflammation itself is dangerous
Inflammatory mediators (IL-1, IL-6, TNF-α) are powerful but indiscriminate — they damage healthy tissue along with pathogens. Since trauma already involves extensive tissue injury, an unchecked inflammatory response risks capillary leakage and progression to multi-organ dysfunction syndrome (MODS) [1]. Historically, dying from one's own hyperinflammatory response was often a greater and more immediate risk than a subsequent infection

2. Timing matters
Following injury, a hyperinflammatory phase (SIRS) and an immune-suppressing counter-response (CARS) develop almost simultaneously, within minutes to days — and it is during this early window that death from organ dysfunction is most likely [1]. Acute tissue damage is immediately life-threatening, on a scale of minutes to hours, while infection typically develops over days. Evolution favored stabilizing the body first and accepting a delayed infection risk over running both processes at full intensity simultaneously.

3. Resources are limited
Mounting and sustaining an immune response is metabolically costly, and organisms operate on a limited energy budget that must be allocated across competing demands such as tissue repair, growth, and defense [2]. After trauma, dampened inflammation frees up resources for wound healing — a process that sustained high cytokine levels can otherwise impair.

4. Guarding against a self-destructive spiral
Damaged tissue releases damage-associated molecular patterns (DAMPs), which activate the immune system much like pathogens do and are now recognized to directly promote the immune suppression seen after trauma, including impaired neutrophil function and expansion of immunosuppressive cell populations [3]. The compensatory anti-inflammatory response acts as a safety brake against a runaway, self-amplifying inflammatory cascade.

5. A mismatch with modern medicine
Evolutionary mismatch occurs when traits shaped by ancestral conditions become poorly suited to a radically different modern environment [4]. This immune-braking program evolved when wounds occurred in unsterile environments and infection was hard to avoid regardless of any inflammatory response mounted. Modern, sterile surgery removes much of that infection risk — yet the same evolutionary braking mechanism still fires, now showing up mainly as an unwanted side effect rather than a useful adaptation.

6. Why this matters most in cancer surgery
Cancer surgery makes this trade-off particularly costly. NK cells are a cornerstone of anti-tumor immunity, eliminating transformed cells without prior sensitization and remaining effective even against tumors that downregulate MHC class I as an immune-evasion strategy. Yet NK cell cytotoxicity is exactly the function most severely and durably suppressed after surgery — activity remains significantly reduced for around two months following major procedures, and the degree of impairment scales with how invasive the surgery is [5, 6, 7]. Cytotoxic T cell function is weakened as well [8].

This creates a dangerous coincidence: the primary tumor is removed at precisely the moment the immune system is least able to police what's left behind. Residual malignant cells, dormant micrometastases, and circulating tumor cells — normally kept in check partly by NK surveillance — face a body that has just had that surveillance capacity switched off, a mechanism increasingly implicated in postoperative recurrence [9] and metastasis [10].

This is where perioperative immunostimulation becomes attractive as a therapeutic strategy: rather than accepting the evolutionary trade-off as fixed, an agent like SilvacxBooster — which mimics viral pattern recognition to drive a type I interferon response and strongly activate NK cells — aims to actively counteract the postoperative immunosuppressive window at exactly the time it matters most, keeping the immune system armed during the vulnerable weeks after tumor removal.